Barriers to utilizing long-acting injectable antipsychotic medications

Area of Science:

• Psychiatry
• Pharmacology
• Mental Health Treatment

Background:

• Long-acting injectable (LAI) antipsychotics offer superior relapse prevention for schizophrenia compared to oral forms.
• Current schizophrenia treatment guidelines and clinical practice in the US underutilize LAI medications.
• A significant gap exists between LAI antipsychotic efficacy and their implementation in patient care.

Purpose of the Study:

• To identify and analyze the barriers encountered by psychiatrists in adopting and utilizing LAI antipsychotic medications for schizophrenia management.
• To understand the factors influencing the underuse of LAI antipsychotics in clinical practice.

Main Methods:

• An online survey was administered to psychiatrists affiliated with Michigan State University.
• The survey collected data on practice characteristics, access to LAI medications, psychiatrists' opinions, and perceived barriers to LAI utilization.
• Thirty-six psychiatrists completed the survey, providing insights into their experiences with LAI antipsychotics.

Main Results:

• 83% of surveyed psychiatrists recognized patients who would benefit from LAI antipsychotics, but only 61% had the capacity to administer them.
• Primary barriers identified include insufficient ancillary support, a preference for oral antipsychotic formulations, and restricted insurance coverage for LAIs.
• Psychiatrists with the capability to administer LAIs were significantly more likely to prescribe them (10 times) than those without.

Conclusions:

• Psychiatrists in Michigan encounter substantial obstacles to the effective implementation of LAI antipsychotic treatments.
• Addressing these barriers is crucial for improving schizophrenia care and increasing the utilization of evidence-based LAI therapies.